Status:
COMPLETED
Speech Analysis in ALS Patients
Lead Sponsor:
Barrow Neurological Institute
Collaborating Sponsors:
Arizona State University
Conditions:
ALS
Amyotrophic Lateral Sclerosis
Eligibility:
All Genders
21+ years
Brief Summary
The purpose of this study is to find out if changes in speech can signal changes in the ability to think or remember. ALS patients with and without cognitive dysfunction will be followed for one year....
Detailed Description
Cognitive dysfunction is increasingly recognized as a core feature of amyotrophic lateral sclerosis (ALS). With appropriate testing, up to 50% of ALS patients will show evidence of frontotemporal dysf...
Eligibility Criteria
Inclusion
- male or female, age 21 or older,
- diagnosed with definite, probable, or possible ALS according to the modified El Escorial Criteria,
- a score of 2 or greater on the speech question of the ALSFRS-R (i.e. speech is intelligible with occasional repetition),
- continuous internet access at home,
- willingness and medical ability to comply with scheduled visits and study procedures,
- ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (PHI) in accordance with national and local subject privacy regulations,
- geographic accessibility to study site,
- for the 25 participants in Group 1, NO noted symptoms of frontotemporal cognitive dysfunction, and
- for the 25 participants in Group 2, MUST have cognitive symptoms as noted either by themselves or a caregiver.
Exclusion
- unwilling or unable to comply with the requirements of this protocol, including the presence of any condition (physical, mental, or social) that is likely to affect the participant's ability to comply with the protocol, and
- any other reasons that, in the opinion of the PI, cause the candidate to be deemed unsuitable for entry into the study.
Key Trial Info
Start Date :
February 18 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 30 2021
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT03868345
Start Date
February 18 2019
End Date
April 30 2021
Last Update
March 9 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Barrow Neurological Institute
Phoenix, Arizona, United States, 85013